Abstract

Introduction and aim: Inflammation plays a very important role in acute ischemic stroke (AIS) and various inflammatory markers are known to be associated with the prognosis of AIS. In this study, we aimed to evaluate the relationship of the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI), which are two new inflammatory markers, with mortality and prognosis in patients with COVID-19 and AIS. Methods:Ninety-fivepatients with COVID-19 who were followed up for AIS were included in this study. SIRI and SII values were calculated using laboratory data at admission. The patients were divided into two groups according to prognosis and mortality. The modified Rankin scale (mRS) was used for prognosis at 3 months and mRS 0-2 was considered a good prognosis. Laboratory parameters neutrophil/lymphocyte ratio (NLR), SII, and SIRI values were compared between the groups according to prognosis and mortality. Results:The NLR, SII, and SIRI values were found to be significantly higher in the poor prognosis group and the group with mortality (p<0.001). As NLR increased, the risk of poor prognosis increased 1.122 times. Asthe SII value increased, the risk of poor prognosis increased 2.978 times, and as SIRI increased, the risk of poor prognosis increased 1.815 times (p<0.001). Conclusion: Our findings show that SIRI and SII are associated with prognosis and mortality in patients with COVID-19 and AIS. Low SIRI and SII values are associated with good clinical outcomes.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call